SGMT SGMT
Company Profile ↓Company Overview
SGMT (SGMT) is a publicly traded company listed on with a market capitalization of $280.99M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +4.73% |
| 6 Months: | +31.71% |
| 3 Months: | +11.92% |
| 1 Month: | +12.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 2.00M | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 19.86M | 11.93M | 14.33M | 10.77M | 11.71M |
| Operating Income | - | -7.24M | -7.69M | -6.76M | -7.06M | -7.45M | -8.77M | -10.59M | -16.90M | -19.86M | -11.93M | -14.33M | -10.77M | -11.71M |
| EBITDA | - | - | - | - | - | - | - | - | - | -19.86M | -11.93M | -14.33M | -10.77M | -11.71M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -18.18M | -10.39M | -12.91M | -9.57M | -10.65M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.73M | -7.10M | -7.47M | -6.59M | -6.79M | -6.35M | -6.63M | -8.12M | -14.62M | -18.18M | -10.39M | -12.91M | -9.57M | -10.65M |
| Diluted EPS | - | -38.37 | -40.34 | -35.58 | -35.80 | -0.35 | -0.23 | -0.25 | -0.45 | -0.56 | -0.32 | -0.40 | -0.29 | -0.33 |
| R&D Expense | - | 6.37M | 6.84M | 4.49M | 4.68M | 4.96M | 5.26M | 6.31M | 12.65M | 15.34M | 7.25M | 9.73M | - | 7.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 2.00M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 31.05M | 32.74M | 54.45M | 56.89M |
| Operating Income | - | -31.05M | -30.74M | -54.45M | -56.89M |
| EBITDA | - | -31.05M | -30.74M | -54.45M | -56.89M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -30.50M | -27.88M | -45.57M | -51.04M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -30.50M | -27.88M | -45.57M | -51.04M |
| Diluted EPS | - | -1.38 | -2.66 | -1.45 | -1.58 |
| R&D Expense | - | 24.92M | 19.78M | 38.44M | 39.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 33.03M | 96.72M | 160.26M | 116.48M |
| Current Assets | - | 32.79M | 96.65M | 152.77M | 116.40M |
| Cash & Equivalents | - | 158.00K | 75.14M | 75.84M | 35.02M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 219.98M | 5.65M | 4.45M | 5.10M |
| Current Liabilities | - | 5.28M | 5.65M | 4.45M | 5.10M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 211.00K | 65.00K | 78.00K | 78.00K |
| Total Equity | - | -186.95M | 91.06M | 155.81M | 111.38M |
| Shares Outstanding | - | 22.17M | 22.90M | 32.20M | 32.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -24.49M | -23.77M | -42.44M | -45.65M |
| Investing Cash Flow | - | -32.01M | 12.58M | -61.68M | 4.56M |
| Financing Cash Flow | - | -73.00K | 86.17M | 104.82M | 275.00K |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | -24.49M | -23.77M | -42.44M | -45.65M |
| Net Change in Cash | - | -56.57M | 74.98M | 701.00K | -40.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | -1,537.0% | - | - |
| Net Margin % | - | - | -1,393.8% | - | - |
| ROE % | - | 16.3% | -30.6% | -29.2% | -45.8% |
| ROCE % | - | -111.9% | -33.8% | -35.0% | -51.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SGMT
Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion
Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple. On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focu…
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced …
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a tre…
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reductions in cholesterol levels, suggesting …
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings e…
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of F…
SGMT — Frequently Asked Questions
What is the current share price of SGMT?
As of 2026-08-05 17:25 PDT, SGMT trades at $8.64 on NASDAQ/NYSE. Its 52-week range is $4.55 to $9.58.
What is the market capitalisation of SGMT?
SGMT has a market capitalisation of $280.99M on NASDAQ/NYSE.
What is the P/E ratio of SGMT?
SGMT trades at a trailing price-to-earnings (P/E) ratio of -5.47. Its price-to-book (P/B) ratio is 2.52.
What is the return on equity (ROE) of SGMT?
SGMT has a return on equity (ROE) of -45.82%. Its return on capital employed (ROCE) is -51.08%.
Is SGMT a good stock to buy?
This page provides a data-driven analysis of SGMT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.